Clear Cell Carcinomas of Müllerian Type and Rete Testis Origin Presenting as Scrotal Masses: A Study of Seven Cases.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Ovarian-type epithelial tumors involving the testis and paratestis are rare, with clear cell carcinomas (CCC) one of the least frequent. We report our experience with 4 müllerian-type (MT) CCCs presenting as testicular/scrotal masses and arising in the paratestis (n=2) and seminal vesicle (n=2; well supported in 1 case and likely in the other). In addition, we document 3 cases of papillary CCC exclusively within the rete testis (RTCCC) and seminiferous tubules and differing from the MT tumors. The patients with MTCCC were 24 to 85 years old (median, 42 y), and 2 had metastases at presentation. The 2 originating in the paratestis were associated with other MT tumors, an endometrioid borderline tumor and a papillary serous borderline tumor. The other 2 MTCCCs likely involved the testis via extension from seminal vesicle primaries through the vasa deferentia. All MTCCCs showed typical features, including tubules, simple papillae with hyalinized cores, and solid nests of polygonal clear cells with occasional hobnail features. Both paratesticular primaries showed sarcomatoid foci with tumor-associated neutrophilic infiltrates. The 3 RTCCCs presented in 54-, 57-, and 60-year-old men as testicular masses; they showed intrarete arborizing papillary growth with nonhyalinized fibrous cores and piled-up, solid foci, lacked hobnail cells, and expressed carbonic anhydrase IX (2/2) and CD10 (2/2) but not CA125, unlike the MTCCCs. On follow-up, 2 patients with MTCCC died of metastatic tumor (4 and 13.5 mo), a third developed ileal and retroperitoneal metastases at 13 months; and the fourth died at 13.5 months of unspecified cause. Follow-up of 2 patients with RTCCCs showed 1 disease free at 8 months and another alive with unknown disease status at 13 years. We conclude that CCCs involving the testis may either be of MT with often aggressive courses or show some features of renal tumors, with confinement to the rete testis and indolent behavior.
Identifiants
pubmed: 38990735
doi: 10.1097/PAS.0000000000002287
pii: 00000478-990000000-00392
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Young RH, Scully RE. Testicular and paratesticular tumors and tumor-like lesions of ovarian common epithelial and mullerian types. A report of four cases and review of the literature. Am J Clin Pathol. 1986;86:146–152.
McClure RF, Keeney GL, Sebo TJ, et al. Serous borderline tumor of the paratestis: a report of seven cases. Am J Surg Pathol. 2001;25:373–378.
Burger T, Schildhaus HU, Inniger R, et al. Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis. Diagn Pathol. 2015;10:118.
Gwiti P, Vereczkey I, Cundell D, et al. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series. Histopathology. 2017;71:686–692.
Alvarado-Cabrero I, Valencia-Cedillo R, Estevez-Castro R, et al. High-grade serous carcinoma of the testis and paratestis: a case series of 29 cases (abstract). Lab Invest. 2023;103(suppl 100090):S687.
Ulbright TM, Young RH. Primary mucinous tumors of the testis and paratestis: a report of nine cases. Am J Surg Pathol. 2003;27:1221–1228.
Teo CH, Chua WJ, Consigliere DT, et al. Primary intratesticular mucinous cystadenocarcinoma. Pathology. 2005;37:92–94.
Scholz B, Beckert M, Mordstein V, et al. Seromucinous borderline tumor of the testis-A case report. Hum Pathol. 2017;60:188–191.
Pratap K, Perera M, Malczewski F, et al. Borderline mucinous testicular tumour: diagnostic and management difficulties. BMJ Case Rep. 2018;2018:bcr2017223787.
Funada S, Yoshida T, Ito M, et al. Primary borderline mucinous tumors of the testis: a case report and literature review. Case Rep Oncol Med. 2015;2015:863745.
Caccamo D, Socias M, Truchet C. Malignant Brenner tumor of the testis and epididymis. Arch Pathol Lab Med. 1991;115:524–527.
Teilum G. Histogenesis and classification of mesonephric tumors of the female and male genital system and relationship to benign so-called adenomatoid tumors (mesotheliomas). A comparative histological study. Arch Pathol Microbiol Scand. 1954;34:431–481.
Tulunay O, Gogus C, Baltaci S, et al. Clear cell adenocarcinoma of the tunica vaginalis of the testis with an adjacent uterus-like tissue. Pathol Int. 2004;54:641–647.
Lin M, Awalt H, Ayala AG, et al. Clear cell carcinoma of testis: A review. Ann Diagn Pathol. 2019;40:26–29.
Fleshman RL, Wasman JK, Bodner DG, et al. Mesodermal adenosarcoma of the testis. Am J Surg Pathol. 2005;29:420–423.
Thomas AZ, McDermott TE, Crowther S, et al. Primary clear cell carcinoma of the rete testis: 1st report. BMJ Case Rep. 2015;2015:bcr2014209000.
Acosta AM, Idrees MT, Collins K, et al. Primary Mullerian-type clear cell carcinoma of the seminal vesicle presenting as a testicular mass. Histopathology. 2023;83:997–999.
Al-Obaidy KI, Collins K, Idrees MT, et al. Adenocarcinoma of the rete testis: seven additional cases, including exclusively and predominantly intrarete tumors. Am J Surg Pathol. 2021;45:1720–1724.
Al-Obaidy KI, Idrees MT, Grignon DJ, et al. Adenocarcinoma of the rete testis: clinicopathologic and immunohistochemical characterization of 6 cases and review of the literature. Am J Surg Pathol. 2019;43:670–681.
Shevchuk MM, Winkler-Monsanto B, Fenoglio CM, et al. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer. 1981;47:1344–1351.
Scully RE, Barlow JF. “Mesonephroma” of ovary. Tumor of Müllerian nature related to the endometrioid carcinoma. Cancer. 1967;20:1405–1417.
Fadare O, Parkash V. Pathology of endometrioid and clear cell carcinoma of the ovary. Surg Pathol Clin. 2019;12:529–564.
Ohta Y, Suzuki T, Shiokawa A, et al. Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2005;24:239–245.
He H, Zhou GX, Zhou M, et al. The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray. Int J Gynecol Pathol. 2011;30:425–430.
Luong-Player A, Liu H, Wang HL, et al. Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol. 2014;141:219–225.
Jiang T, Diao X, Ding M, et al. SR-B1 and CD10 combined immunoprofile for differential diagnosis of metastatic clear cell renal cell carcinoma and clear cell carcinoma of the ovary. J Mol Histol. 2021;52:539–544.
Rekhi B, Deodhar KK, Menon S, et al. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. APMIS. 2018;126:45–55.
Pors J, Segura S, Cheng A, et al. Napsin-A and AMACR are superior to HNF-1β in distinguishing between mesonephric carcinomas and clear cell carcinomas of the gynecologic tract. Appl Immunohistochem Mol Morphol. 2020;28:593–601.
Hoang LN, Han G, McConechy M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 2014;64:585–596.
Iwamoto M, Nakatani Y, Fugo K, et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol. 2015;46:957–962.
Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol. 2015;28:111–117.
Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol. 2001;25:667–672.
DeLair D, Oliva E, Köbel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 2011;35:36–44.
Yamamoto S, Tsuda H, Yoshikawa T, et al. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol. 2007;31:999–1006.
Lim D, Ip PP, Cheung AN, et al. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol. 2015;39:1061–1069.
Campobasso D, Fornia S, Ferretti S, et al. Primary bilateral seminal vesicle carcinoma: description of a case and literature review. Int J Surg Pathol. 2012;20:633–635.
Murakami H, Motoshima T, Kurahashi R, et al. Clear cell carcinoma of the seminal vesicle in a young adult. IJU case reports. 2022;5:406–409.
Ohmori T, Okada K, Tabei R, et al. CA 125-producing adenocarcinoma of the seminal vesicle. Pathol Int. 1994;44:333–337.
Sterling ME, Kovell RC, Jaffe WI. Primary seminal vesicle adenocarcinoma presenting with bilateral orbital metastasis: a case report. Urology Case Rep. 2016;6:33–35.
Grosser D, Matoso A, Epstein JI. Clear cell adenocarcinoma in men: a series of 15 cases. Am J Surg Pathol. 2021;45:270–276.
Jones MA, Young RH, Scully RE. Adenocarcinoma of the epididymis: a report of four cases and review of the literature. Am J Surg Pathol. 1997;21:1474–1480.
Sundarasivarao D. The mullerian vestiges and benign epithelial tumors of the epididymis.. J Pathol Bacteriol. 1953;66:417–431.
Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816–826.
Hu Y, Hartmann A, Stoehr C, et al. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol. 2012;65:254–256.
Paner GP, Srigley JR, Radhakrishnan A, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30:13–19.
Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69–76.
Xu B, Abourbih S, Sircar K, et al. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases. Appl Immunohistochem Mol Morphol. 2014;22:206–212.
Zhu B, Rohan SM, Lin X. Immunoexpression of napsin A in renal neoplasms. Diagn Pathol. 2015;10:4.
Baniak N, Flood TA, Buchanan M, et al. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology. 2020;77:659–666.
Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009;33:241–247.
Went P, Dirnhofer S, Salvisberg T, et al. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol. 2005;29:83–88.
Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747–754.
Mazal PR, Stichenwirth M, Koller A, et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005;18:535–540.
Walter B, Hartmann A, Hofstädter F, et al. Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria. Virchows Arch. 2012;460:343–352.
Martignoni G, Pea M, Brunelli M, et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004;17:1455–1463.
Cox R, Vang R, Epstein JI. Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma. Am J Surg Pathol. 2014;38:713–718.